Chairman Shin Dong-guk of Hanyang Precision acquired an additional 6.45% stake in Hanmi Science, raising his and the company’s combined holding to nearly 30%, amid heightened management tensions with Hanmi Pharmaceutical’s CEO.
#YonhapInfomax #HanmiScience #ShinDongGuk #StakeAcquisition #HanyangPrecision #ManagementDispute #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=106455
Chairman Shin Dong-guk Acquires Additional 6.45% Stake in Hanmi Science—Holding Approaches 30%
Chairman Shin Dong-guk of Hanyang Precision acquired an additional 6.45% stake in Hanmi Science, raising his and the company’s combined holding to nearly 30%, amid heightened management tensions with Hanmi Pharmaceutical’s CEO.
Hanmi Science Unveils Three Surgical Hemostatic Agents at World’s Largest Medical Device Expo
Hanmi Science Co., Ltd. will unveil three new surgical hemostatic agents at MEDICA 2025 in Düsseldorf, aiming to expand its global presence and forge new partnerships in key international markets.
Hanmi Science Co. reported a 75.2% year-on-year surge in Q3 operating profit to 39.3 billion won, driven by strong healthcare and pharmaceutical distribution sales, while key subsidiary Hanmi Pharmaceutical advanced global competitiveness through new drug developments and international partnerships.
#YonhapInfomax #HanmiScience #OperatingProfit #HealthcareBusiness #HanmiPharmaceutical #Q3Earnings #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=87930
Hanmi Science Posts 75.2% Surge in Q3 Operating Profit to 39.3 Billion Won—Driven by Healthcare and Distribution Gains (Comprehensive)
Hanmi Science Co. reported a 75.2% year-on-year surge in Q3 operating profit to 39.3 billion won, driven by strong healthcare and pharmaceutical distribution sales, while key subsidiary Hanmi Pharmaceutical advanced global competitiveness through new drug developments and international partnerships.
Hanmi Science and Hanmi Pharmaceutical have both been upgraded to 'AA-' by NICE Investors Service, reflecting robust financial health and industry-leading competitiveness in South Korea's pharmaceutical sector.
#YonhapInfomax #HanmiScience #HanmiPharmaceutical #NICEInvestorsService #CreditRating #FinancialStability #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=85224
Hanmi Science and Hanmi Pharmaceutical Secure 'AA-' Rating—'Industry's Highest Level'
Hanmi Science and Hanmi Pharmaceutical have both been upgraded to 'AA-' by NICE Investors Service, reflecting robust financial health and industry-leading competitiveness in South Korea's pharmaceutical sector.
Hanmi Science Co. reported a 30.7% year-on-year jump in Q2 operating profit to 34.6 billion won, driven by balanced growth across healthcare and distribution units, while expanding its business portfolio and focusing on new drug technology exports.
#YonhapInfomax #HanmiScience #OperatingProfit #Q2Earnings #HealthcareBusiness #TechnologyExports #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=73917
Hanmi Science Posts Q2 Operating Profit of 34.6 Billion Won, Up 30.7% Year-on-Year—“Broad-Based Growth” (Comprehensive)
Hanmi Science Co. reported a 30.7% year-on-year jump in Q2 operating profit to 34.6 billion won, driven by balanced growth across healthcare and distribution units, while expanding its business portfolio and focusing on new drug technology exports.
Hanmi Science Posts Q2 Operating Profit of 34.6 Billion Won, Up 30.7% Year-on-Year
Hanmi Science reports robust Q2 results with operating profit surging 30.7% year-on-year to 34.6 billion won, signaling strong growth momentum.
Hanmi Science Q1 Operating Profit at 27 Billion Won - Down 27.4% Year-on-Year (Update)
Hanmi Science reports Q1 operating profit of 27 billion won, down 27.4% year-on-year, despite 3.8% increase in sales to 332.1 billion won
HanmiScience Q1 Operating Profit at 27 Billion Won, Down 27.4% Year-on-Year
HanmiScience reports significant decline in Q1 operating profit, reflecting challenging market conditions in pharmaceutical sector
La Defense - 'Enhancing Hanmi Science's Governance Transparency... Maximizing Shareholder Value'
La Defense Partners aims to enhance Hanmi Science's governance transparency and maximize shareholder value, purchasing additional shares amid recent stock price decline.
Hanmi Science CEO Kim Jae-gyo - 'Challenging to Develop Innovative Global New Drugs'
Hanmi Science CEO Kim Jae-gyo announces focus on innovative global drug development, restructures organization to enhance strategic growth and innovation capabilities
Yonhap Infomax News